• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

免疫抑制性肿瘤微环境中髓源性抑制细胞与调节性T细胞之间的功能串扰

The Functional Crosstalk between Myeloid-Derived Suppressor Cells and Regulatory T Cells within the Immunosuppressive Tumor Microenvironment.

作者信息

Haist Maximilian, Stege Henner, Grabbe Stephan, Bros Matthias

机构信息

Department of Dermatology, University Medical Center of the Johannes Gutenberg University, 55131 Mainz, Germany.

出版信息

Cancers (Basel). 2021 Jan 8;13(2):210. doi: 10.3390/cancers13020210.

DOI:10.3390/cancers13020210
PMID:33430105
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7827203/
Abstract

Immune checkpoint inhibitors (ICI) have led to profound and durable tumor regression in some patients with metastatic cancer diseases. However, many patients still do not derive benefit from immunotherapy. Here, the accumulation of immunosuppressive cell populations within the tumor microenvironment (TME), such as myeloid-derived suppressor cells (MDSC), tumor-associated macrophages (TAM), and regulatory T cells (Treg), contributes to the development of immune resistance. MDSC and Treg expand systematically in tumor patients and inhibit T cell activation and T effector cell function. Numerous studies have shown that the immunosuppressive mechanisms exerted by those inhibitory cell populations comprise soluble immunomodulatory mediators and receptor interactions. The latter are also required for the crosstalk of MDSC and Treg, raising questions about the relevance of cell-cell contacts for the establishment of their inhibitory properties. This review aims to outline the current knowledge on the crosstalk between these two cell populations, issuing particularly the potential role of cell adhesion molecules. In this regard, we further discuss the relevance of β2 integrins, which are essential for the differentiation and function of leukocytes as well as for MDSC-Treg interaction. Lastly, we aim to describe the impact of such bidirectional crosstalk for basic and applied cancer research and discuss how the targeting of these pathways might pave the way for future approaches in immunotherapy.

摘要

免疫检查点抑制剂(ICI)已使一些转移性癌症患者实现了深度且持久的肿瘤消退。然而,许多患者仍无法从免疫疗法中获益。肿瘤微环境(TME)中免疫抑制细胞群体的积累,如髓源性抑制细胞(MDSC)、肿瘤相关巨噬细胞(TAM)和调节性T细胞(Treg),导致了免疫抗性的产生。MDSC和Treg在肿瘤患者体内系统性扩增,并抑制T细胞活化和T效应细胞功能。众多研究表明,这些抑制性细胞群体发挥的免疫抑制机制包括可溶性免疫调节介质和受体相互作用。后者也是MDSC和Treg相互作用所必需的,这引发了关于细胞间接触对于其抑制特性建立的相关性的疑问。本综述旨在概述目前关于这两种细胞群体间相互作用的知识,特别关注细胞黏附分子的潜在作用。在这方面,我们进一步讨论β2整合素的相关性,其对于白细胞的分化和功能以及MDSC-Treg相互作用至关重要。最后,我们旨在描述这种双向相互作用对基础和应用癌症研究的影响,并讨论靶向这些途径如何可能为未来的免疫治疗方法铺平道路。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c67/7827203/412c270aa7d6/cancers-13-00210-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c67/7827203/a6bc8f4e3320/cancers-13-00210-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c67/7827203/2d1ac363b21c/cancers-13-00210-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c67/7827203/412c270aa7d6/cancers-13-00210-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c67/7827203/a6bc8f4e3320/cancers-13-00210-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c67/7827203/2d1ac363b21c/cancers-13-00210-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c67/7827203/412c270aa7d6/cancers-13-00210-g003.jpg

相似文献

1
The Functional Crosstalk between Myeloid-Derived Suppressor Cells and Regulatory T Cells within the Immunosuppressive Tumor Microenvironment.免疫抑制性肿瘤微环境中髓源性抑制细胞与调节性T细胞之间的功能串扰
Cancers (Basel). 2021 Jan 8;13(2):210. doi: 10.3390/cancers13020210.
2
Therapeutic prospects of targeting myeloid-derived suppressor cells and immune checkpoints in cancer.靶向髓系来源抑制细胞和癌症免疫检查点的治疗前景。
Immunol Cell Biol. 2018 Oct;96(9):888-897. doi: 10.1111/imcb.12054. Epub 2018 Apr 22.
3
Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression.靶向髓系来源抑制细胞以绕过肿瘤诱导的免疫抑制。
Front Immunol. 2018 Mar 2;9:398. doi: 10.3389/fimmu.2018.00398. eCollection 2018.
4
Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors.髓源性抑制细胞阻碍免疫检查点抑制剂的抗癌活性。
Front Immunol. 2018 Jun 11;9:1310. doi: 10.3389/fimmu.2018.01310. eCollection 2018.
5
Immunostimulatory RNA leads to functional reprogramming of myeloid-derived suppressor cells in pancreatic cancer.免疫刺激 RNA 导致胰腺癌中髓源性抑制细胞的功能重编程。
J Immunother Cancer. 2019 Nov 6;7(1):288. doi: 10.1186/s40425-019-0778-7.
6
Myeloid derived suppressor cells in tumor microenvironment: Interaction with innate lymphoid cells.肿瘤微环境中的髓源性抑制细胞:与固有淋巴细胞的相互作用。
Semin Immunol. 2022 Nov;61-64:101668. doi: 10.1016/j.smim.2022.101668. Epub 2022 Nov 9.
7
Expression of costimulatory and inhibitory receptors in FoxP3 regulatory T cells within the tumor microenvironment: Implications for combination immunotherapy approaches.肿瘤微环境中 FoxP3 调节性 T 细胞中共刺激和共抑制受体的表达:对联合免疫治疗方法的影响。
Adv Cancer Res. 2019;144:193-261. doi: 10.1016/bs.acr.2019.05.001. Epub 2019 Jun 6.
8
Myeloid-Derived Suppressor Cells in the Tumor Microenvironment.肿瘤微环境中的髓源性抑制细胞。
Adv Exp Med Biol. 2020;1224:117-140. doi: 10.1007/978-3-030-35723-8_8.
9
[Immune cell contexture in the tumor microenvironment].[肿瘤微环境中的免疫细胞构成]
Rinsho Ketsueki. 2020;61(9):1424-1432. doi: 10.11406/rinketsu.61.1424.
10
Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression.肿瘤进展过程中髓源性抑制细胞(MDSCs)介导的免疫抑制。
Br J Cancer. 2019 Jan;120(1):16-25. doi: 10.1038/s41416-018-0333-1. Epub 2018 Nov 9.

引用本文的文献

1
Immunomodulatory Natural Products in Cancer Organoid-Immune Co-Cultures: Bridging the Research Gap for Precision Immunotherapy.癌症类器官-免疫共培养中的免疫调节天然产物:弥合精准免疫治疗的研究差距
Int J Mol Sci. 2025 Jul 26;26(15):7247. doi: 10.3390/ijms26157247.
2
Immunosuppressive cells in acute myeloid leukemia: mechanisms and therapeutic target.急性髓系白血病中的免疫抑制细胞:机制与治疗靶点
Front Immunol. 2025 Jul 23;16:1627161. doi: 10.3389/fimmu.2025.1627161. eCollection 2025.
3
Decoding the metabolic dialogue in the tumor microenvironment: from immune suppression to precision cancer therapies.

本文引用的文献

1
The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion.癌症免疫治疗的新时代:靶向髓系来源抑制细胞以克服免疫逃逸。
Front Immunol. 2020 Jul 30;11:1680. doi: 10.3389/fimmu.2020.01680. eCollection 2020.
2
Neutrophil diversity and plasticity in tumour progression and therapy.中性粒细胞的多样性和可塑性在肿瘤进展和治疗中的作用。
Nat Rev Cancer. 2020 Sep;20(9):485-503. doi: 10.1038/s41568-020-0281-y. Epub 2020 Jul 21.
3
Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects.
解码肿瘤微环境中的代谢对话:从免疫抑制到精准癌症治疗
Exp Hematol Oncol. 2025 Jul 22;14(1):99. doi: 10.1186/s40164-025-00689-6.
4
The HIF axes in cancer: angiogenesis, metabolism, and immune-modulation.癌症中的缺氧诱导因子轴:血管生成、代谢及免疫调节。
Trends Biochem Sci. 2025 Aug;50(8):677-694. doi: 10.1016/j.tibs.2025.06.005. Epub 2025 Jul 9.
5
Tiragolumab and TIGIT: pioneering the next era of cancer immunotherapy.替雷利珠单抗与TIGIT:开创癌症免疫治疗的新时代。
Front Pharmacol. 2025 Jun 11;16:1568664. doi: 10.3389/fphar.2025.1568664. eCollection 2025.
6
Balancing Regeneration and Resistance: Targeting DCLK1 to Mitigate Gastrointestinal Radiation Injury and Oncogenesis.平衡再生与抗性:靶向双皮质素样激酶1以减轻胃肠道辐射损伤和肿瘤发生
Cancers (Basel). 2025 Jun 19;17(12):2050. doi: 10.3390/cancers17122050.
7
Osteosarcoma immune microenvironment: cellular struggle and novel therapeutic insights.骨肉瘤免疫微环境:细胞斗争与新的治疗见解
Front Immunol. 2025 Jun 4;16:1584450. doi: 10.3389/fimmu.2025.1584450. eCollection 2025.
8
Emerging frontiers in adoptive cell therapies: innovations, challenges, and future perspectives.过继性细胞疗法的新兴前沿领域:创新、挑战与未来展望。
Med Oncol. 2025 Jun 15;42(7):261. doi: 10.1007/s12032-025-02808-z.
9
CD300a: An Innate Immune Checkpoint Shaping Tumor Immunity and Therapeutic Opportunity.CD300a:一个塑造肿瘤免疫和治疗机会的先天性免疫检查点
Cancers (Basel). 2025 May 27;17(11):1786. doi: 10.3390/cancers17111786.
10
Exploring the immune environment of glioblastoma through single-cell RNA sequencing in humanized mouse models.通过人源化小鼠模型中的单细胞RNA测序探索胶质母细胞瘤的免疫环境。
bioRxiv. 2025 May 22:2025.05.17.654526. doi: 10.1101/2025.05.17.654526.
肿瘤微环境中的调节性 T 细胞:新机制、潜在治疗策略和未来前景。
Mol Cancer. 2020 Jul 17;19(1):116. doi: 10.1186/s12943-020-01234-1.
4
Metabolic Modulation of Immunity: A New Concept in Cancer Immunotherapy.代谢免疫调节:癌症免疫治疗的新概念。
Cell Rep. 2020 Jul 7;32(1):107848. doi: 10.1016/j.celrep.2020.107848.
5
Galectin-9 promotes a suppressive microenvironment in human cancer by enhancing STING degradation.半乳糖凝集素-9通过增强干扰素基因刺激蛋白(STING)的降解,促进人类癌症中的抑制性微环境。
Oncogenesis. 2020 Jul 6;9(7):65. doi: 10.1038/s41389-020-00248-0.
6
Biological Factors behind Melanoma Response to Immune Checkpoint Inhibitors.黑色素瘤对免疫检查点抑制剂反应的生物学因素。
Int J Mol Sci. 2020 Jun 6;21(11):4071. doi: 10.3390/ijms21114071.
7
Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma.现代免疫疗法中的黑色素瘤检查点抑制剂。
Int J Mol Sci. 2020 Mar 30;21(7):2367. doi: 10.3390/ijms21072367.
8
Glutathione Restricts Serine Metabolism to Preserve Regulatory T Cell Function.谷胱甘肽限制丝氨酸代谢以维持调节性 T 细胞功能。
Cell Metab. 2020 May 5;31(5):920-936.e7. doi: 10.1016/j.cmet.2020.03.004. Epub 2020 Mar 25.
9
Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer.髓源性抑制细胞作为癌症治疗靶点。
Cells. 2020 Feb 27;9(3):561. doi: 10.3390/cells9030561.
10
β2 Integrins-Multi-Functional Leukocyte Receptors in Health and Disease.β2 整合素:健康与疾病中的多功能白细胞受体。
Int J Mol Sci. 2020 Feb 19;21(4):1402. doi: 10.3390/ijms21041402.